Evidence map›Paper›PMID 20980828›Full record

ArticleCancer biology & therapy2010

Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice.

Hong Shen-Li, Susan Koujak, Matthias Szablocs, Ramon Parsons

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. PTEN in Hereditary and Sporadic Cancer.Cold Spring Harbor perspectives in medicine · 2020
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Regulation of PTEN expression by noncoding RNAs.Journal of experimental & clinical cancer research : CR · 2018
    Review
  14. Article
  15. PTEN function: the long and the short of it.Trends in biochemical sciences · 2014
    Review
  16. Article
  17. Genetic alterations of PTEN in human melanoma.Cellular and molecular life sciences : CMLS · 2012
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hong Shen-LiInstitute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA.
Susan Koujak
Matthias Szablocs
Ramon Parsons
Columbia University Irving Medical Center · USCancer Genetics (United States) · US

Funding

PTEN TUMOR SUPPRESSOR AND SIGNAL TRANSDUCTIONR01CA082783 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PARSONS, RAMON E · 2001 to 2016
$3.8M
NCI NIH HHS CA082783NCI NIH HHS R01 CA082783
6 · The paper itself

Abstract

To address the impact of partial reduction of Pten on tumor initiation, we generated PtenshRNA mice, in which PTEN expression was reduced below normal levels in various tissues. PtenshRNA mice frequently developed lymphoid and prostatic hyperplasia, splenomegaly, and sebaceous adenomas. Our observations support the notion that partial reduction of the dose of Pten with shRNA is sufficient to induce neoplastic disease in multiple organ systems.

Indexed as

AdenomaAdrenal GlandsAnimalsBrainEndometriumFemaleHyperplasiaLymphatic DiseasesMaleMiceMice, Inbred C57BLMice, TransgenicNeoplasms, ExperimentalOrgan SizePhosphorylationProstatic HyperplasiaProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseRNA, Small Interfering

Identifiers

PMID20980828
PMCPMC3018670
OpenAlexW2065827515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.